Literature DB >> 30747837

The Impact of Early Clinical and Subclinical T Cell-mediated Rejection After Kidney Transplantation.

William Hoffman1, Rajil Mehta1, Dana R Jorgensen1, Puneet Sood1, Parmjeet Randhawa2, Christine M Wu1, Chetan Puttarajappa1, Nirav A Shah1, Amit D Tevar3, Sundaram Hariharan1.   

Abstract

BACKGROUND: We investigated the effect of clinical and subclinical T cell-mediated rejection (C-TCMR and SC-TCMR) on allograft histology, function, and progression.
METHODS: Adult kidney recipients with 2 protocol biopsies were divided into No-TCMR on biopsies (n = 104), SC-TCMR (n = 56), and C-TCMR (n = 32) in at least 1 biopsy. Chronicity (ci + ct + cg + cv) scores, renal function, and the burden of renal disease measured by area under the curve (serum creatinine, mg mo/dL) were compared.
RESULTS: Baseline characteristics were similar except for mean donor age and Kidney Donor Profile index scores. Patients with C-TCMR had higher mean serum creatinine, lower mean estimated glomerular filtration rate, and higher area under the curve with 95% confidence interval (75.2 [67.7-82.7]) as opposed to patients with SC-TCMR and No-TCMR (58.3 [53.6-62.9], 65.1 [58.8-71.5]), P = 0.0004. Chronicity scores were higher at 3 months in C-TCMR (2.30 ± 1.58) compared with SC-TCMR (2.02 ± 1.42) and No-TCMR (1.31 ± 1.18), P = 0.0001 and also at 12 months. At last follow-up, 18.8% patients with C-TCMR had ≥50% decline in estimated glomerular filtration rate from 3 months compared with 7% and 1% among No-TCMR and SC-TCMR groups (P = 0.038). Multivariate analyses revealed higher odds of Δ-creatinine ≥ 0.5 mg/dL from 3 months to last follow-up for C-TCMR (3.39 [95% confidence interval, 1.25-9.20]) versus No-TCMR (P = 0.016).
CONCLUSIONS: Kidney transplant recipients with C-/SC-TCMR have heightened early allograft chronicity and worse renal function compared with those with No-TCMR. Progressive renal dysfunction was noted among patients with C-TCMR as opposed to SC-TCMR and No-TCMR.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30747837     DOI: 10.1097/TP.0000000000002560

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Two Can Be Better Than One: Improving Noninvasive Diagnostics in Kidney Transplantation.

Authors:  Calla Khilnani; Peter S Heeger
Journal:  Clin J Am Soc Nephrol       Date:  2021-10       Impact factor: 10.614

2.  Transcriptional dissection of differentially expressed long non-coding RNAs and messenger RNAs reveals the potential molecular mechanism after kidney transplantation.

Authors:  Hengcheng Zhang; Guodong Shi; Qingqiao Hu; Henglu Zhang; Ming Zheng; Kuirong Jiang; Min Gu
Journal:  Ann Transl Med       Date:  2019-09

3.  Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers.

Authors:  Chethan M Puttarajappa; Rajil B Mehta; Mark S Roberts; Kenneth J Smith; Sundaram Hariharan
Journal:  Am J Transplant       Date:  2020-07-15       Impact factor: 8.086

4.  The negative impact of T cell-mediated rejection on renal allograft survival in the modern era.

Authors:  Christie Rampersad; Robert Balshaw; Ian W Gibson; Julie Ho; Jamie Shaw; Martin Karpinski; Aviva Goldberg; Patricia Birk; David N Rush; Peter W Nickerson; Chris Wiebe
Journal:  Am J Transplant       Date:  2021-11-24       Impact factor: 9.369

5.  Impact of Subclinical Borderline Inflammation on Kidney Transplant Outcomes.

Authors:  Michael E Seifert; Gaurav Agarwal; Miriam Bernard; Ellen Kasik; S Sikandar Raza; Huma Fatima; Robert S Gaston; Vera Hauptfeld-Dolejsek; Bruce A Julian; Clifton E Kew; Vineeta Kumar; Shikha Mehta; Song Ong; Frida Rosenblum; Graham Towns; Roslyn B Mannon
Journal:  Transplant Direct       Date:  2021-01-26

Review 6.  Therapies for Chronic Allograft Rejection.

Authors:  Min Young Kim; Daniel C Brennan
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

7.  Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort.

Authors:  Scott Davis; Christopher Wiebe; Kristen Campbell; Cheri Anobile; Michael Aubrey; Erik Stites; Monica Grafals; Elizabeth Pomfret; Peter Nickerson; James E Cooper
Journal:  Am J Transplant       Date:  2020-10-11       Impact factor: 8.086

8.  Clinical Relevance of Corticosteroid Withdrawal on Graft Histological Lesions in Low-Immunological-Risk Kidney Transplant Patients.

Authors:  Domingo Hernández; Juana Alonso-Titos; Teresa Vázquez; Myriam León; Abelardo Caballero; María Angeles Cobo; Eugenia Sola; Verónica López; Pedro Ruiz-Esteban; Josep María Cruzado; Joana Sellarés; Francesc Moreso; Anna Manonelles; Alberto Torío; Mercedes Cabello; Juan Delgado-Burgos; Cristina Casas; Elena Gutiérrez; Cristina Jironda; Julia Kanter; Daniel Serón; Armando Torres
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

9.  Impact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol.

Authors:  Itunu Owoyemi; Srijan Tandukar; Dana R Jorgensen; Christine M Wu; Puneet Sood; Chethan Puttarajappa; Akhil Sharma; Nirav A Shah; Parmjeet Randhawa; Michele Molinari; Amit D Tevar; Rajil B Mehta; Sundaram Hariharan
Journal:  Transplant Direct       Date:  2021-06-08

10.  Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection.

Authors:  Chris Wiebe; David N Rush; Ian W Gibson; Denise Pochinco; Patricia E Birk; Aviva Goldberg; Tom Blydt-Hansen; Martin Karpinski; Jamie Shaw; Julie Ho; Peter W Nickerson
Journal:  Am J Transplant       Date:  2020-04-09       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.